{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T17:11:45Z","timestamp":1795194705078,"version":"4.10.3"},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011094","name":"Public Health Agency of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011094","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.vaccine.2023.12.068","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T16:03:03Z","timestamp":1704816183000},"page":"535-540","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Prospective monitoring of adverse events following vaccination with Modified vaccinia Ankara - Bavarian Nordic (MVA-BN) administered to a Canadian population at risk of Mpox: A Canadian Immunization Research Network study"],"prefix":"10.1016","volume":"42","author":[{"given":"M.P.","family":"Muller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1660-6169","authenticated-orcid":false,"given":"C.","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8239-0094","authenticated-orcid":false,"given":"S.E.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.P.","family":"Shulha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Naus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Padhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5647-6137","authenticated-orcid":false,"given":"A.","family":"McGeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9492-7277","authenticated-orcid":false,"given":"M.","family":"Finkelstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Liddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2118-4174","authenticated-orcid":false,"given":"J.A.","family":"Bettinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.vaccine.2023.12.068_b0005","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1016\/S1473-3099(22)00574-6","article-title":"Prevention of monkeypox with vaccines: a rapid review","volume":"22","author":"Poland","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2023.12.068_b0010","doi-asserted-by":"crossref","first-page":"e54407","DOI":"10.1371\/journal.pone.0054407","article-title":"Prospective surveillance for cardiac adverse events in healthy adults receiving modified vaccinia Ankara vaccines: a systematic review","volume":"8","author":"Elizaga","year":"2013","journal-title":"PLoS ONE [Electronic Resource]"},{"key":"10.1016\/j.vaccine.2023.12.068_b0015","unstructured":"Canada PHAo. Reporting adverse events following vaccination with Imvamune: Communique to healthcare professionals. Government of Canada. https:\/\/www.canada.ca\/en\/public-health\/services\/diseases\/mpox\/health-professionals\/reporting-adverse-events-following-vaccination-imvamune-communique.html. Published 2022. Accessed 7\/17\/2023, 2023."},{"issue":"1","key":"10.1016\/j.vaccine.2023.12.068_b0020","doi-asserted-by":"crossref","first-page":"67","DOI":"10.7326\/M22-2699","article-title":"Monkeypox in Montreal: Epidemiology, Phylogenomics, and Public Health Response to a Large North American Outbreak","volume":"176","author":"Harrison","year":"2023","journal-title":"Ann Intern Med"},{"issue":"29","key":"10.1016\/j.vaccine.2023.12.068_b0025","doi-asserted-by":"crossref","first-page":"E1031","DOI":"10.1503\/cmaj.220886","article-title":"A case of human monkeypox in Canada","volume":"194","author":"Sukhdeo","year":"2022","journal-title":"CMAJ"},{"key":"10.1016\/j.vaccine.2023.12.068_b0030","unstructured":"Immunization NACo. Smallpox and mpox (monkeypox) vaccine: Canadian Immunization Guide. Government of Canada. https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canadian-immunization-guide-part-4-active-vaccines\/page-21-smallpox-vaccine.html. Published 2023. Accessed 7\/17\/2023, 2023."},{"issue":"20","key":"10.1016\/j.vaccine.2023.12.068_b0035","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1817307","article-title":"Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox","volume":"381","author":"Pittman","year":"2019","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.vaccine.2023.12.068_b0040","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1016\/j.vaccine.2014.02.043","article-title":"Phase II randomized, double-blinded comparison of a single high dose (5x10(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1x10(8) TCID50) in healthy vaccinia-naive individuals","volume":"32","author":"Frey","year":"2014","journal-title":"Vaccine"},{"issue":"43","key":"10.1016\/j.vaccine.2023.12.068_b0045","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1016\/j.vaccine.2014.08.022","article-title":"Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis","volume":"32","author":"von Sonnenburg","year":"2014","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2023.12.068_b0050","doi-asserted-by":"crossref","first-page":"e0122653","DOI":"10.1371\/journal.pone.0122653","article-title":"Cardiac safety of Modified Vaccinia Ankara for vaccination against smallpox in a young, healthy study population","volume":"10","author":"Zitzmann-Roth","year":"2015","journal-title":"PLoS ONE [Electronic Resource]"},{"issue":"1","key":"10.1016\/j.vaccine.2023.12.068_b0055","doi-asserted-by":"crossref","first-page":"e051254","DOI":"10.1136\/bmjopen-2021-051254","article-title":"The Canadian National Vaccine Safety Network: surveillance of adverse events following immunisation among individuals immunised with the COVID-19 vaccine, a cohort study in Canada","volume":"12","author":"Bettinger","year":"2022","journal-title":"BMJ Open"},{"issue":"15","key":"10.1016\/j.vaccine.2023.12.068_b0060","first-page":"2485","article-title":"Uptake of Mpox vaccination among transgender people and gay, bisexual and other men who have sex with men among sexually-transmitted infection clinic clients in Vancouver","volume":"41","author":"Gilbert","year":"2023","journal-title":"British Columbia Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2023.12.068_b0065","doi-asserted-by":"crossref","first-page":"e0157335","DOI":"10.1371\/journal.pone.0157335","article-title":"A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN R) in 56\u201380-Year-Old Subjects","volume":"11","author":"Greenberg","year":"2016","journal-title":"PLoS ONE [Electronic Resource]"},{"issue":"10","key":"10.1016\/j.vaccine.2023.12.068_b0070","doi-asserted-by":"crossref","first-page":"e0138348","DOI":"10.1371\/journal.pone.0138348","article-title":"A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18\u201340 Year Old Subjects with Diagnosed Atopic Dermatitis","volume":"10","author":"Greenberg","year":"2015","journal-title":"PLoS ONE [Electronic Resource]"},{"issue":"4","key":"10.1016\/j.vaccine.2023.12.068_b0075","doi-asserted-by":"crossref","first-page":"e0195897","DOI":"10.1371\/journal.pone.0195897","article-title":"Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial","volume":"13","author":"Overton","year":"2018","journal-title":"PLoS ONE [Electronic Resource]"},{"key":"10.1016\/j.vaccine.2023.12.068_b0080","article-title":"Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial. Open Forum","author":"Overton","year":"201522040","journal-title":"Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2023.12.068_b0085","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1016\/j.vaccine.2020.01.058","article-title":"A randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDS","volume":"38","author":"Overton","year":"2020","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2023.12.068_b0090","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/infdis\/jis753","article-title":"Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects","volume":"207","author":"Greenberg","year":"2013","journal-title":"J Infect Dis"},{"issue":"49","key":"10.1016\/j.vaccine.2023.12.068_b0095","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.15585\/mmwr.mm7149a4","article-title":"Safety Monitoring of JYNNEOS Vaccine During the 2022 Mpox Outbreak - United States, May 22-October 21, 2022","volume":"71","author":"Duffy","year":"2022","journal-title":"MMWR - Morbidity & Mortality Weekly Report"},{"issue":"7","key":"10.1016\/j.vaccine.2023.12.068_b0100","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1097\/JOM.0b013e3181a86671","article-title":"How accurate are self-reports? Analysis of self-reported health care utilization and absence when compared with administrative data","volume":"51","author":"Short","year":"2009","journal-title":"J Occup Environ Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23015141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23015141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:34:10Z","timestamp":1759404850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23015141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0264410X23015141"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.12.068","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prospective monitoring of adverse events following vaccination with Modified vaccinia Ankara - Bavarian Nordic (MVA-BN) administered to a Canadian population at risk of Mpox: A Canadian Immunization Research Network study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.12.068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}